250 related articles for article (PubMed ID: 7742153)
21. In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin.
Desta Z; Soukhova N; Flockhart DA
J Clin Psychopharmacol; 2002 Apr; 22(2):162-8. PubMed ID: 11910261
[TBL] [Abstract][Full Text] [Related]
22. Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.
Olesen OV; Linnet K
J Clin Psychopharmacol; 2000 Feb; 20(1):35-42. PubMed ID: 10653206
[TBL] [Abstract][Full Text] [Related]
23. Are pharmacokinetic drug interactions with the SSRIs an issue?
Brøsen K
Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
25. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
26. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine.
Iribarne C; Picart D; Dréano Y; Berthou F
Fundam Clin Pharmacol; 1998; 12(2):194-9. PubMed ID: 9565774
[TBL] [Abstract][Full Text] [Related]
27. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Exp Toxicol Pathol; 1999 Jul; 51(4-5):309-14. PubMed ID: 10445388
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes.
Facciolá G; Hidestrand M; von Bahr C; Tybring G
Eur J Clin Pharmacol; 2001 Mar; 56(12):881-8. PubMed ID: 11317475
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
Schmider J; Greenblatt DJ; von Moltke LL; Karsov D; Shader RI
Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
[TBL] [Abstract][Full Text] [Related]
32. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
33. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes.
Ueng YF; Jan WC; Lin LC; Chen TL; Guengerich FP; Chen CF
Drug Metab Dispos; 2002 Mar; 30(3):349-53. PubMed ID: 11854157
[TBL] [Abstract][Full Text] [Related]
34. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.
Brøsen K
Clin Pharmacokinet; 1995; 29 Suppl 1():20-5. PubMed ID: 8846619
[TBL] [Abstract][Full Text] [Related]
35. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
J Pharmacol Exp Ther; 1995 Nov; 275(2):592-7. PubMed ID: 7473143
[TBL] [Abstract][Full Text] [Related]
36. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
Rasmussen BB; Nielsen TL; Brøsen K
Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha HR; Chen J; Freiburghaus AU; Follath F
Br J Clin Pharmacol; 1995 Mar; 39(3):321-6. PubMed ID: 7619675
[TBL] [Abstract][Full Text] [Related]
38. Preferential inhibition of CYP1A enzymes in hepatic microsomes by mexiletine.
Konishi H; Morita K; Minouchi T; Yamaji A
Eur J Drug Metab Pharmacokinet; 1999; 24(2):149-53. PubMed ID: 10510742
[TBL] [Abstract][Full Text] [Related]
39. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
40. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
